The second half of the 20th century has seen a constant de-crease in cardiovascular
mortality in the Western industrialised nations [1]. This decrease has occurred concomitantly …

Hypertension is one of the major risk factors for coronary heart disease and the most
important risk factor for cerebrovascular diseases (1). In most countries, almost 20% of the …

Among the various drugs currently available for the treatment of systemic hypertension,
calcium antagonists continue to receive much attention because of their established efficacy …

Lercanidipine has demonstrated a good antihypertensive efficacy and an excellent
tolerability profile, not only in randomized clinical trials but also in daily clinical practice. With …

Systemic hypertension is a major global problem contributing to enormous disease burden,
premature morbidity and mortality. A substantial majority of hypertensive patients require …

Aim: Lercanidipine, a long-acting dihydropyridine with a good antihypertensive efficacy and
tolerability in clinical use. With the aim to determine the efficacy and tolerability of this drug in …

To determine whether the antihypertensive effectiveness of lercanidipine was independent
of the different cardiovascular risk levels. Patients with treated or untreated mild‐to …

Abstract Lercanidipine HCl is a 1, 4-dihydropyridine derivative with potent, long-lasting, and
vascular-selective calcium channel blocking activity. It is approved for the treatment of …

Lercanidipine (Zanidip®) is a vasoselective dihydropyridine calcium channel antagonist that
causes systemic vasodilation by blocking the influx of calcium ions through L-type calcium …

Lercanidipine is a vasoselective dihydropyridine calcium antagonist which causes systemic
vasodilation by blocking the influx of calcium ions through L-type calcium channels in cell …